Inhibition of cytochrome P450 3A by acetoxylated analogues of resveratrol in in vitro and in silico models | Scientific Reports
Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer | Nature Reviews Urology
Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses | Arteriosclerosis, Thrombosis, and Vascular Biology
Mechanisms of resistance to CYP17 inhibitors. Androgen receptor (AR)... | Download Scientific Diagram
Computation | Free Full-Text | Exploring the Chemical Space of Cytochrome P450 Inhibitors Using Integrated Physicochemical Parameters, Drug Efficiency Metrics and Decision Tree Models
Biased cytochrome P450-mediated metabolism via small-molecule ligands binding P450 oxidoreductase | Nature Communications
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases | Nature Reviews Drug Discovery
Evidence-based capacity of natural cytochrome enzyme inhibitors to increase the effectivity of antineoplastic drugs | SpringerLink
CYP17 inhibitors in prostate cancer: latest evidence and clinical potential - Anitha B. Alex, Sumanta K. Pal, Neeraj Agarwal, 2016
Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001 | Nature
APExBIO - TOK-001|CYP17 inhibitor and androgen receptor (AR) antagonist|CAS# 851983-85-2
The influence of steroid metabolism on CYP17A1 inhibitor activity | Nature Reviews Urology
ARe we there yet? Understanding androgen receptor signaling in breast cancer | npj Breast Cancer
CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents | Nature Reviews Urology
CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents | Nature Reviews Urology
Mechanisms of resistance to CYP17 inhibitors. Androgen receptor (AR)... | Download Scientific Diagram
CYP17 inhibitors for prostate cancer therapy - ScienceDirect
CYP17 inhibition as a hormonal strategy for prostate cancer | Nature Reviews Urology
Resistance to second-generation androgen receptor antagonists in prostate cancer | Nature Reviews Urology
Frontiers | Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations | Prostate Cancer and Prostatic Diseases
